Article
Clinical efficacy of icotinib in lung cancer patients with different EGFR mutation status: a meta-analysis.
Oncotarget - 16 May 2017
Qu Jian, Wang Ya-Nan, Xu Ping, Xiang Da-Xiong, Yang Rui, Wei Wei, Qu Qiang
Abstract excerpt
Icotinib is a novel and the third listed epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), which exerts a good anti-tumor efficacy on non-small cell lung cancer (NSCLC). The efficacy of EGFR-TKIs has been shown to be associated with the EGFR mutation status, especially exon 19 deletion (19Del) and exon 21 L858R mutation. Therefore, a meta-analysis was performed to assess the efficacy of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.